HDAC9 and acute myeloid leukemia: Oliver Goodyear et al. reported an increased expression of MAGE-A1 mRNA and protein in acute myeloid leukemia (AML) cell lines after treatment with another hypomethylating agent azacitidine (AZA) alone or in combination with the HDAC inhibitor valproic acid (VPA) [25].